Key terms

About AGIO

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest AGIO news

May 03 6:43am ET RBC Capital Sticks to Their Buy Rating for Agios Pharma (AGIO) by TipRanks May 02 7:05am ET Agios Pharmaceuticals expects cash to fund expenditures at least into 2026 by TipRanks May 02 7:03am ET Agios Pharmaceuticals announces anticipated 2024 milestones by TipRanks May 02 7:02am ET Agios Pharmaceuticals reports Q1 EPS ($1.45), consensus ($1.65) by TipRanks Apr 22 8:32am ET Agios Pharma (AGIO) Receives a Buy from Piper Sandler by TipRanks Apr 08 10:50pm ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Gilead Sciences (GILD) and Agios Pharma (AGIO) by TipRanks Mar 14 12:50pm ET Cantor Fitzgerald biotech analysts hold an analyst/industry conference call by TipRanks Mar 14 11:41am ET Cantor Fitzgerald biotech analysts hold an analyst/industry conference call by TipRanks Feb 26 11:01am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Feb 26 11:01am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Feb 18 11:46pm ET Optimistic Outlook for Agios Pharma: A Buy Rating Amidst Pyrukynd Sales Miss and Promising ENERGIZE-T Trial Prospects by TipRanks Feb 16 5:08am ET Buy Rating for Agios Pharma Amid Expanding Drug Pipeline and Strong Commercial Prospects by TipRanks Feb 15 4:05pm ET Buy Rating Justified by Agios Pharma’s Promising Trials and Future Prospects by TipRanks Feb 15 7:03am ET Agios Pharmaceuticals reports 2023 EPS ($6.33), consensus ($6.26) by TipRanks Feb 08 7:21am ET Agios Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald by TipRanks

No recent press releases are available for AGIO

AGIO Financials

1-year income & revenue

Key terms

AGIO Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

AGIO Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Warren Buffett (L), CEO of Berkshire Hathaway, and Vice Chairman Charlie Munger attend the 2019 annual shareholders meeting in Omaha, Nebraska, May 3, 2019.
Johannes Eisele/AFP/Getty Images
Warren Buffett holds first Berkshire Hathaway meeting without Charlie Munger
People walk by the New York Stock Exchange (NYSE) on March 20, 2024 in New York City. The Dow was up slightly in late morning trading as traders analyze the Federal Reserve's latest decision on interest rates.
Spencer Platt/Getty Images
Stocks close higher after softer-than-expected jobs report fuels hopes of an earlier rate cut
People work at a Starbucks in Manhattan on February 02, 2024 in New York City.
Spencer Platt/Getty Images
Restaurants are competing for frugal diners’ dollars
Traders work on the floor of the New York Stock Exchange during afternoon trading on April 09, 2024 in New York City.
Michael M. Santiago/Getty Images/File
Sell in May and go away? Think again